sampling, processing, evaluation tools, classification and interpretation are key for differential diagnosis and management. The need of standardizing histopathology classification that can be used worldwide is essential. Peña AS (1), provide a very useful tabulated comparison among different classifications, facilitating the interpretation of publications using various classifications, allowing for compilation and analysis of data for public health. The idea of reassessing the emphasis on the biopsy as a gold standard in the diagnosis of CD, in light of available less invasive tests, is a welcoming one, at least reducing the number of biopsies required for follow up. Villanacci (2) emphasizes on reproducibility and the use of simpler classification to facilitate reproducibility, but his suggested classification seems over simplified. Clinicians shall decide if that will be sufficient for proper Dx and management. Villanacci (2, 3) points out the advantage of including the term of "Microscopic Enteritis" (4) as a separate histopathology Dx, a practical suggestion for differential diagnosis. Marsh, Villanacci and, Srivastava (5) illustrate the differences between the histopathology of CD Marsh classification (4), and non-celiac gluten sensitivity. Despite its limited explanation, this publication is very useful to pathologists. Could this classification be
LETTER TO EDITOR
modified not to use morphometric analysis? Do the Villanaci (2, 3) simplified classification provide the information required for best practice? These questions need consensual response for best practice guidelines worldwide. Nonetheless and until proven otherwise evaluation of new therapeutic products are best to use the Marsh classification (5). It calls my attention that in this discussion there is no mention of differences in diagnostic approach between pediatric and adult cases, since the need for the use of biopsy in pediatric has been questioned. Do you have any thoughts on that? The concern expressed by Walker (6) is a valid one, but if anything is complementary to Peña AS (1) editorial. International guidelines cited are the key to standardization on diagnosis and management of CD, and gluten free-diet (GFD) as the therapy of choice, which carries an emotional, and financial impact. The ACG Clinical Guidelines: Diagnosis and Management of CD published by Rubio-Tapia et al. (6) indicates that a diagnosis of CD requires the demonstration of histological changes associated with the disease, classified according to: Marsh, Marsh modified (Oberhuber), or by the more recent, simplified Corazza classification. It accepts the incorporation of simplified classifications for the general practice.
